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Acute-on-chronic liver failure (ACLF) in cirrhosis is characterized by acute decompensation (AD), organ failure(s), and high
short-term mortality. Recently, we have proposed (systemic inflammation [SI] hypothesis) that ACLF is the expression of an
acute exacerbation of the SI already present in decompensated cirrhosis. This study was aimed at testing this hypothesis and
included 522 patients with decompensated cirrhosis (237 with ACLF) and 40 healthy subjects. SI was assessed by measuring
29 cytokines and the redox state of circulating albumin (HNA2), a marker of systemic oxidative stress. Systemic circulatory dys-
function (SCD) was estimated by plasma renin (PRC) and copeptin (PCC) concentrations. Measurements were performed at
enrollment (baseline) in all patients and sequentially during hospitalization in 255. The main findings of this study were: (1)
Patients with AD without ACLF showed very high baseline levels of inflammatory cytokines, HNA2, PRC, and PCC.
Patients with ACLF showed significantly higher levels of these markers than those without ACLF; (2) different cytokine pro-
files were identified according to the type of ACLF precipitating event (active alcoholism/acute alcoholic hepatitis, bacterial
infection, and others); (3) severity of SI and frequency and severity of ACLF at enrollment were strongly associated. The course
of SI and the course of ACLF (improvement, no change, or worsening) during hospitalization and short-term mortality were
also strongly associated; and (4) the strength of association of ACLF with SI was higher than with SCD. Conclusion: These
data support SI as the primary driver of ACLF in cirrhosis. (HEPATOLOGY 2016;64:1249-1264).
Abbreviations: AAH, acute alcoholic hepatitis; ACLF, acute-on-chronic liver failure; ACLF-RF, ACLF with renal failure; AD, acute decompensa-
tion; ADH, antidiuretic hormone; AST, aspartate aminotransferase; CI, confidence interval; CLIF, chronic liver failure; CRP, C-reactive protein;
Cys34, cysteine-34; DAMPs, damage-associated molecular patterns; EGF, epidermal growth factor; G-CSF, granulocyte colony-stimulating factor;
GM-CSF, granulocyte macrophage colony-stimulating factor; HMA, human mercaptalbumin; HNA1, reversibly oxidized human nonmercaptalbumin
1; HNA2, irreversibly oxidized human nonmercaptalbumin 2; IFNc, interferon gamma; IP-10, IFNc-inducible protein 10; IQR, interquartile range;
IL, interleukin; LT, liver transplantation; MCP-1, macrophage chemotactic protein 1; MIP, macrophage inflammatory protein; PAMPs, pathogen-
associated molecular patterns; PCC, plasma copeptin concentration; PE, precipitating event; PRC, plasma renin concentration; RR, relative risk; SCD,
systemic circulatory dysfunction; SI, systemic inflammation; SIRS, systemic inflammatory response syndrome; TNFa, tumor necrosis factor alpha; VEGF,
vascular endothelial growth factor; WBC, white blood cell count.
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cute-on-chronic liver failure (ACLF) in cir-
rhosis is a highly prevalent syndrome char-
acterized by acute decompensation (AD),
organ/system failure(s), and high 28-day mortality
(32%).(1) ACLF is classified in three grades of
severity (ACLF-I, -II, and -III) according to the
number of organ failures and may follow four differ-
ent clinical courses during hospitalization: resolu-
tion, improvement (reduction in ACLF grade),
steady course, or worsening.(2)
The systemic inflammation (SI) hypothesis(3) pro-
poses that ACLF is attributed to aggravation of the
SI and associated systemic circulatory dysfunction
(SCD) already present in AD, which leads to organ
failure(s) as a consequence of organ hypoperfusion
and direct deleterious effects of inflammatory media-
tors on the organ microcirculation and cell physiology
homeostasis. According with this hypothesis, AD
would occur in the setting of chronic SI attributable
to translocation of proinflammatory molecules (path-
ogen-associated molecular patterns; PAMPs) from
the intestinal lumen to the systemic circulation and/
or to the release or damage-associated molecular pat-
terns (DAMPs) from the diseased liver or another
organ. ACLF would be the result of further increase
of SI in the context of precipitating events (PEs;
mainly active alcoholism/acute alcoholic hepatitis
[AAH], bacterial infections, or other Pes). The SI
hypothesis was based on cytokine studies in small
series of patients(4-7) and on the CANONIC study,
in which a close relationship between blood
leukocytes (white blood cell count; WBC) and C-
reactive protein (CRP) levels and the presence and
severity of ACLF was observed.(1)
In the current study, we assessed the SI hypothesis
by two approaches. The first was aimed at examining
the relationship between markers of SI, measured at
enrollment and sequentially during hospitalization,
and the presence, severity, and clinical course of
ACLF and associated mortality in 552 patients hospi-
talized for AD. The second approach was aimed at
assessing whether, as proposed by the SI hypothesis,
ACLF in cirrhosis is not only attributed to an accentu-
ation of the SCD and organ hypoperfusion related to
SI, but also to direct deleterious effects of SI in organ
function. This assessment was performed by assessing





AND DIAGNOSTIC CRITERIA OF
ORGAN FAILURE AND ACLF
Two hundred thirty-seven patients with ACLF,
either present at enrollment (n 5 180) or developed
during hospitalization (n 5 57), and 285 without
ACLF derived from the CANONIC investigation(1)
were studied. Selection criteria were: (1) availability of
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blood samples at enrollment and (2) prospective inten-
sive surveillance during hospitalization. Follow-up plas-
ma samples obtained at prespecified visits during
hospitalization (2, 3-7, 8-14, 15-21, and 22-28 days
after enrollment) were available in 255 patients, 157
with ACLF. Sequential blood samples before ACLF, at
ACLF diagnosis, and during post-ACLF follow-up
were available in 20 of the 57 patients developing
ACLF during hospitalization. In the remaining patients
with ACLF, there were only samples at ACLF diagno-
sis and during follow-up. Samples were obtained in
2011 in Vacutainer ethylenedimainetetraacetic acid
tubes, centrifuged at 48C, and the plasma frozen at -
908C. Measurements were performed during 2015.
Clinical, laboratory, and follow-up data were obtained
from individual electronic CRF. There was no patient
with human immunodeficiency virus infection. Diagnosis
of organ failure, ACLF, and ACLF grades are based on
the Chronic Liver Failure (CLIF) Consortium Organ
Failure score and the CANONIC study criteria(1,8) (see
Supporting Information). Clinical diagnosis of AAH was
based on the National Institute on Alcohol Abuse and
Alcoholism Alcoholic Hepatitis Consortia criteria(9):
active alcoholism, serum bilirubin >3 mg/dL, aspartate
aminotransferase (AST) >50 IU/mL, and AST/alanine
aminotransferase ratio >1.5. As described,(10) systemic
inflammatory response syndrome (SIRS) was defined by
the presence of alterations in at least two of the following
parameters: WBC count, heart and respiratory rates, and
body temperature.
CHARACTERIZATION OF SI IN
AD: RELATIONSHIP WITH ACLF
To characterize SI, we measured the plasma levels of
29 cytokines involved in innate and adaptive immune
responses and the redox state of circulating albumin
(a marker of systemic oxidative stress(11,12)). Baseline
measurements were obtained at enrollment in all patients.
In addition, a second baseline measurement was obtained
at ACLF diagnosis in 20 of the 57 patients developing
ACLF during hospitalization. To assess the role of SI in
the pathogenesis of ACLF, we compared baseline plasma
cytokine levels of patients with and without ACLF at
enrollment and examined the relationship between these
measurements and ACLF severity. Also, we assessed the
chronological relationship between changes in SI and the
course of ACLF during hospitalization by comparing
the levels of SI markers at ACLF diagnosis with those at
the last measurement during hospitalization (before dis-
charge or liver transplantation [LT] or death). Median
time from enrollment to last assessment: 15 days (percen-
tile 25-75:7-28). Differences in baseline cytokine profiles
according to the etiology (PE) were also assessed to iden-
tify potential differences in SI mechanisms. Finally,
proinflammatory/anti-inflammatory cytokine ratios were
determined in healthy subjects and patients with and
without ACLF to assess the profile of proinflammatory
and anti-inflammatory cytokine response in these
patients. Cytokines were measured using a multiplexed
bead-based immunoassay on a Luminex 100 Bioanalyzer
(Austin, TX) (Supporting Information and Supporting
Table S1).
Systemic oxidative stress was estimated by measuring
the percentage of albumin oxidized at the cysteine-34
(Cys34) residue over the total albumin concentration.
Free Cys34 accounts for around 80% of the antioxidant
capacity of human plasma.(12,13) In the presence of sys-
temic oxidative stress, Cys34 is converted from the
reduced form with Cys34 in the free sulphydryl form
(human mercaptalbumin; HMA) to mixed disulfides
(human nonmercaptalbumin 1; HNA1). This process is
reversible.(14-16) A smaller fraction of Cys34, however, is
highly oxidized to sulfenic, sulfinic, and, finally, sulfonic
forms (human nonmercaptalbumin 2; HNA2). Oxida-
tion of albumin to HNA2 is irreversible and causes
intense modifications of the protein structure.(15,16)
HNA11HNA2 as well as HNA2 were used as markers
of systemic oxidative stress.(17-19) Reasons for the selec-
tion of the redox state of albumin over other markers of
systemic oxidative stress and the methodology of mea-
surement are detailed in the Supporting Information.
STRENGTH OF THE
ASSOCIATION OF MARKERS OF
SI AND OF SCD WITH ACLF OR
ACLF WITH RENAL FAILURE
Systemic circulatory function defines a series of
physiological processes influencing the cardiac output
and activity of endogenous vasoactive systems that reg-
ulate arterial pressure and global organ perfusion. Micro-
circulatory function (which is mainly dependent on
endothelial and tissue factors) regulates the blood and
oxygen delivery to the cells. Given that plasma renin con-
centration (PRC) and the plasma concentration of
copeptin (PCC) are very sensitive to changes in effective
circulating blood volume,(20,21) they were selected as
markers of SCD for this study. Copeptin is a stable cleav-
age product of the C-terminal part of the antidiuretic
hormone (ADH) precursor that is produced in a 1:1
fashion with ADH. It is widely used to estimate
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vasopressin release because it allows an easier, more-
accurate immunological testing than ADH.(21) Other cri-
teria used for selection of PRC and PCC as markers of
systemic circulatory dysfunction and the methodology of
measurements are detailed in the Supporting Informa-
tion. Copeptin (as ADH) is filtered by the glomeruli and
therefore may overestimate ADH secretion in patients
with ACLF with renal failure (ACLF-RF).
The strength of the association of ACLF with PRC
and with interleukin (IL)-8, IL-6, or HNA2 was esti-
mated to assess whether ACLF is related not only to
SCD, but also to other effects of SI in organ function.
IL-8, IL-6, and HNA2 were selected because they were
the inflammatory markers more strongly associated with
ACLF in our patients (see Results). PRC was selected
because it was not influenced, as copeptin, by glomerular
filtration rate in our patients (see Results). The strength
of the association of ACLF-RF with markers of SI and
PRC were also compared as an outcome, given that renal
failure is a paradigmatic organ failure in cirrhosis thought
to be caused by severe impairment in cardiovascular func-
tion and organ hypoperfusion.(3,20,22) Four different
approaches to analysis were used.
First, we visually assessed the distribution of baseline
IL-8, IL-6, HNA2, and PRC according to the pres-
ence of ACLF and ACLF-RF by means of a scatter-
plot of patients’ values. The strength of association
between SI or SCD and ACLF or ACLF-RF was
estimated by comparing (chi-square tests) the progres-
sion of ACLF or ACLF-RF frequency at three differ-
ent levels (tertiles) of each SI marker versus PRC.
Second, we assessed the percentage of patients with
ACLF or ACLF-RF showing normal levels of IL-8,
IL-6, HNA2, and PRC.
The third approach included two different analyses:
(1) a logistic regression model to assess which markers
(IL-8, IL-6, HNA2, and/or PRC) were independently
associated with the presence of ACLF or ACLF-RF
and (2) a linear regression model assessing the correla-
tion of IL-8, IL-6, HNA2, and PRC with CLIF Con-
sortium Organ Failure score and serum creatinine as
markers of ACLF and renal impairment severity.
Finally, we assessed the association of changes inmarkers
of SI and PRC during hospitalization with changes in the
clinical course of patients with andwithout ACLF.
SI, SCD, AND MORTALITY
We also assessed the strength of the association of
baseline levels of SI and SCD markers and of changes
in these markers during hospitalization with short-
term (28-day and 90-day) mortality.
DATA ANALYSIS AND
STATISTICAL DETAILS
Among the 29 cytokines determined, 12 were undetect-
able in a high percentage (more than 30%) of the patients
with cirrhosis studied (Supporting Table S2). Because of
this feature, two independent analyses on the association
of cytokines with ACLF and mortality were performed.
The main analysis, which included the 17 cytokines show-
ing detectable plasma levels in most patients, is detailed in
the main body of the article. Undetectable levels of healthy
subjects in this analysis (the majority of values for some
cytokines) were assigned a value equal to the lower limit of
detection. The second analysis was performed with the 12
cytokines with more than 30% of undetectable values.
Results with this group are briefly mentioned in the text of
the article and detailed in the Supporting Information.
Discrete variables are shown as counts (percentage)
and continuous variables as mean (SD). Non-normally
distributed variables are summarized by the median
(interquartile range; IQR) and were log-transformed
for some statistical analyses and for graphical compari-
sons. In univariate statistical comparisons, the chi-
square test was used for categorical variables, whereas
the Student t test or analysis of variance were used for
normal continuous variables and the Wilcoxon signed-
rank test or the Kruskall-Wallis test for continuous
variables not normally distributed. In all statistical
analyses, significance was set at P < 0.05.
Results
CHARACTERIZATION OF SI IN
PATIENTS WITH AD:
RELATIONSHIP WITH ACLF
Patient characteristics were similar to those of the
whole CANONIC cohort(1) (Supporting Table S3).
Active alcoholism and bacterial infections were the
most frequent PEs of ACLF, although in approximately
40% of patients no PE was identified. The presence and
severity of ACLF and prognosis correlated closely with
WBC and CRP levels. The prevalence of AAH (47
patients) among the 522 patients studied was only of
9% (65% among the 72 patients with active alcoholism).
AAH was significantly more frequent in patients with
ACLF (12.2%) than in those without ACLF (6.3%;
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P < 0.05). Only 78 patients (14.9%) showed SIRS.
SIRS was significantly more frequent (P < 0.05) in
patients with bacterial infection (23.6% vs. 11.9%),
AAH (25.5% vs. 13.9%), or ACLF (19.9% vs. 10.9%).
Tables 1 and 2 show the results obtained with the
17 cytokines with detectable values in more than 70%
of the patients. They were categorized as either cyto-
kines with predominant inflammatory properties
(tumor necrosis factor alpha [TNFa], IL-6, IL-8,
macrophage chemotactic protein 1 [MCP-1], interfer-
on gamma [IFNc]-inducible protein 10 [IP-10], mac-
rophage inflammatory protein [MIP]-1b, granulocyte
colony-stimulating factor [G-CSF], and granulocyte
macrophage colony-stimulating factor [GM-CSF]) in
the innate immune system, cytokines with predomi-
nant anti-inflammatory properties (IL-10 and IL-1ra),
or cytokines with other actions, including cytokines
with predominant activity in the adaptive immune sys-
tem (IFNc, IFNa2, IL-17a, and IL-7), cytokines with
predominant chemotactic activity on eosinophils
(eotaxin), and cytokines that function as growth factors
(epidermal growth factor [EGF] and vascular endothe-
lial growth factor [VEGF]; Supporting Table S4).
As compared to healthy controls, patients with cir-
rhosis showed markedly increased levels of all cytokines
(Table 1). Patients presenting ACLF exhibited signifi-
cantly higher levels of proinflammatory cytokines than
patients without ACLF. The anti-inflammatory cyto-
kines, IL-10 and IL-1ra, followed a similar pattern. In
contrast, differences in plasma levels of the remaining
cytokines were slight or not significant. No significant
differences in plasma cytokine levels at ACLF diagno-
sis were observed between patients with ACLF at
enrollment and those who developed ACLF after
enrollment (data not shown).
There was a clear, direct relationship between intensi-
ty of SI and severity of ACLF, as indicated by a parallel
and significant increase in IL-6, IL-8, and IL-1ra from
ACLF grade I to ACLF grades II and III (Table 2).
IL-8/IL-10 and IL-6/IL-10 ratios were determined
as markers of proinflammatory/anti-inflammatory cyto-
kine response (Supporting Fig. S1). The two ratios were
TABLE 1. Plasma Concentrations of Renin (PRC), Copeptin (PCC), and Cytokines and Albumin






N 5 237 P Value*
Markers of SCD
PRC (microIU/mL) 8 (6-17) 65 (17-242) 134 (36-378) <0.001
PCC (pmol/L) 0 (0-10) 9 (3-23) 31 (13-61) <0.0001
Proinflammatory cytokines
TNFa (pg/mL) 9 (7-12) 20 (14-27) 29 (17-41) <0.001
IL-6 (pg/mL) 0.3 (0.3-0.3) 21 (11-41) 39 (17-115) <0.001
IL-8 (pg/mL) 1.6 (0.6-3.3) 37 (20-76) 84 (41-169) <0.001
MCP-1 (pg/mL) 337 (218-413) 318 (228-436) 410 (288-713) <0.001
IP-10 (pg/mL) 328 (234-428) 965 (558-1,676) 1,184 (665-2,157) 0.004
MIP-1b (pg/mL) 13 (6-17) 20 (13-34) 28 (19-50) <0.001
G-CSF (pg/mL) 2.1 (1.8-11) 23 (11-50) 32 (14-83) 0.001
GM-CSF (pg/mL) 7.5 (7.5-7.5) 4.7 (2.0-9.5) 7.3 (3.5-16.8) <0.001
Anti-inflammatory cytokines
IL-10 (pg/mL) 1.1 (0.4-1.1) 3.4 (1.1-9.2) 8.1 (2.1-29.9) <0.001
IL-1ra (pg/mL) 7 (3-9) 10 (5-22) 23 (9-63) <0.001
Other cytokines
IFNc (pg/mL) 0.8 (0.8-4.9) 6 (2-18) 7 (3-24) 0.044
IFNa2 (pg/mL) 3 (3-3) 22 (8-56) 27 (11-63) 0.113
Eotaxin (pg/mL) 94 (55-122) 110 (81-155) 124 (89-179) 0.018
IL-17a (pg/mL) 0.7 (0.7-2.7) 3.7 (1.6-10.3) 4.5 (1.6-15.6) 0.128
IL-7 (pg/mL) 1.4 (0.1-3.9) 2.6 (1.0-8.5) 3.5 (1.6-11.1) 0.012
EGF (pg/mL) 17 (4-29) 26 (9-66) 19 (8-41) 0.046
VEGF (pg/mL) 26 (26-28) 85 (28-226) 91 (29-252) 0.745
Albumin oxidation fractions†
HMA (%) 71 (68-74) 53 (42-62) 45 (33-56) <0.001
HNA11HNA2 (%) 28 (25-30) 46.4 (37.5-56.9) 51.8 (42.2-65.6) <0.001
HNA2 (%) 1.3 (0.3-1.9) 4.5 (2.5-8.8) 9.8 (5.6-14.8) <0.001
Data are median (IQR).
*P value between ACLF and NO ACLF.
†According to the redox state at Cys34.
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significantly higher in patients with cirrhosis than in
healthy subjects. No significant differences between
patients with and without ACLF were observed.
Supporting Tables S5 and S6 show the results
obtained with the cytokines showing detectable values
in less than 70% of patients. All cytokines included in
this analysis were also significantly higher in patients
with decompensated cirrhosis with and without ACLF
than in healthy controls (Supporting Table S5). How-
ever, significant differences between patients with and
without ACLF were observed only in the inflammato-
ry cytokine, MIP-1a (higher in patients with ACLF).
Among the cytokines included in this analysis, only
IL-15 was significantly different across the three
grades of severity of ACLF (Supporting Table S6).
The profile of the 17 cytokines included in the main
analysis varied according to the PEs in patients with
ACLF (Table 3). ACLF precipitated by bacterial
infection showed higher levels of TNFa, IL-6, and
IL-1ra than ACLF precipitated by active alcoholism
(P 5 0.004, P 5 0.02, and P 5 0.0269, respectively)
or ACLF associated with other PEs or without PE
(P 5 0.04, P 5 0.0002, and P 5 0.02, respectively).
ACLF precipitated by active alcoholism showed higher
levels of IL-8 than ACLF precipitated by bacterial
infection (P 5 0.0001) or ACLF associated with other
PEs or without PE (P 5 0.001). The cytokine profile
in ACLF precipitated by both bacterial infections and
active alcoholism shared the characteristics of
ACLF precipitated by infection and active alcoholism
alone. In ACLF patients with other PEs or without
PE, no cytokine showed significantly increased levels
in comparison to the other groups of patients with
ACLF.
Supporting Table S7 shows that the profile associated
with active alcoholism was attributed, to a great extent, to
the extremely high values of IL-8 observed in patients
with AAH. However, the plasma levels of IL-8 were also
higher in patients with active alcoholism without AAH
than in those without active alcoholism (Supporting
Table S7). This increase in plasma levels of IL-8 observed
in patients with alcoholic cirrhosis and active alcoholism
TABLE 2. Plasma Concentrations of Renin (PRC), Copeptin (PCC), and Cytokines and Albumin Oxidation Fractions






N 5 25 P Value*
Markers of SCD
PRC (microIU/mL) 169 (40-383) 114 (28-352) 87 (33-258) 0.771
PCC (pmol/L) 34 (16.62) 27 (13-45) 47 (11.134) 0.224
Proinflammatory cytokines
TNFa (pg/mL) 30 (21-43) 26 (15-36) 32 (17-43) 0.029
IL-6 (pg/mL) 34 (18-96) 43 (13-106) 111 (32-355) 0.018
IL-8 (pg/mL) 62 (37-112) 97 (48-192) 144 (80-292) <0.001
MCP-1 (pg/mL) 412 (299-633) 376 (277-646) 660 (322-1,773) 0.089
IP-10 (pg/mL) 1,218 (717-2,258) 1,162 (617-1,946) 1,689 (899-2,728) 0.267
MIP-1b (pg/mL) 27 (18-43) 28 (19-55) 46 (20-61) 0.112
G-CSF (pg/mL) 32 (15-70) 29 (14-81) 39 (15-209) 0.673
GM-CSF (pg/mL) 6.8 (3.7-15.0) 7.5 (2.7-20.1) 11.3 (5.1-29.6) 0.512
Anti-inflammatory cytokines
IL-10 (pg/mL) 4.3 (1.1-17.9) 15.3 (5.5-41.5) 12.4 (6.6-40.8) <0.001
IL-1ra (pg/mL) 17 (10-45) 26 (8-63) 49 (24-135) 0.019
Other cytokines
IFNc (pg/mL) 7 (3-24) 9 (3-25) 7 (2-16) 0.906
IFNa2 (pg/mL) 27 (11-61) 25 (12-74) 30 (12-55) 0.968
Eotaxin (pg/mL) 124 (90-178) 128 (90-180) 103 (87-176) 0.951
IL-17a (pg/mL) 3.4 (1.6-13.3) 5.5 (1.8-27.8) 8.1 (1.5-15.2) 0.623
IL-7 (pg/mL) 3.5 (1.7-8.0) 3.8 (1.4-14.6) 3.5 (2.1-6.9) 0.790
EGF (pg/mL) 20 (9-51) 19 (7-38) 14 (7-25) 0.233
VEGF (pg/mL) 95 (28-246) 77 (27-278) 89 (35-201) 0.950
Albumin oxidation fractions†
HMA (%) 44 (33-56) 45 (32-58) 51 (42-58) 0.621
HNA11HNA2 (%) 52.9 (42.2-64.0) 51.3 (42.2-66.9) 48.7 (41.8-58.3) 0.781
HNA2 (%) 9.5 (5.1-13.9) 9.8 (5.6-15.1) 11.1 (7.8-15.1) 0.205
Data are median (IQR).
*Comparison between ACLF grades.
†According to the redox state at Cys34.
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but no AAH was not detected in alcoholic patients with
cirrhosis who stopped drinking (Supporting Table S7).
Supporting Table S8 shows the cytokine profile in
patients with and without SIRS. Patients with SIRS
showed significantly higher plasma levels of the proin-
flammatory cytokines, IL-6, IL-8, MCP-1, MIP-1b,
and G-CSF, and of the anti-inflammatory cytokines,
IL-10 and IL-1ra, than patients without SIRS.
HNA11HNA2 and HNA2 were markedly increased
(P < 0.001) in patients with cirrhosis with and without
ACLF as compared to healthy controls (Table 1). Values
for both HNA11HNA2 and HNA2 were significantly
higher in patients with ACLF than in those without
(Table 1). There were no significant changes in the redox
state of albumin across the three ACLF grades (Table 2).
SCD IN PATIENTS WITH AND
WITHOUT ACLF
PRC and PCC were markedly above normal range
in patients with and without ACLF, but values of
these markers were significantly higher in the former
than in the latter group (Table 1). PCC was signifi-
cantly higher in patients with ACLF-RF (48.7 [19.8-
81.1]) than in those with ACLF without renal failure
(25.1 [10.2-44.8] pmol/L; P < 0.001). In contrast, no
significant differences in PRC were observed between
these two groups (112 [35-276] vs. 179 [33-460]
microIU/mL; P 5 0.285). These results indicate that
PCC is a poor marker of SCD in patients with
ACLF-RF given that it reflects not only an increased
release of the ADH precursor by the neurohypophysis
as a consequence of SCD, but also an impaired renal
clearance of copeptin. PCC values in patients with
ACLF without renal failure were significantly higher
than those observed in the group of patients without
ACLF (25.1 [10.2-44.8] vs. 9 [3-23] pmol/L; P <
0.001), indicating that ADH secretion is markedly
increased in ACLF. No significant changes in PRC
and PCC were observed across the three ACLF grades
(Table 2).
TABLE 3. Plasma Concentrations of Renin (PRC), Copeptin (PCC), and Cytokines and Albumin Oxidation Fractions













(n 5 19) P Value*
Markers of SCD
PRC (microIU/mL) 151 (50-474) 164 (28-447) 92 (31-295) 205 (112-998) 69 (25-210) 0.3021
PCC (pmol/L) 31 (15-59) 38 (16-64) 24 (7-36) 33 (4-112) 34 (16-55) 0.4654
Proinflammatory cytokines
TNFa (pg/mL) 29 (17-41) 32 (26-47) 21 (14-32) 34 (18-53) 27 (20-35) 0.0256
IL-6 (pg/mL) 30 (14-69) 72 (28-358) 37 (13-122) 83 (34-466) 34 (21-104) 0.0002
IL-8 (pg/mL) 64 (38-104) 92 (47-167) 211 (141-351) 158 (99-310) 50 (28-92) <0.0001
MCP-1 (pg/mL) 372 (279-484) 512 (299-1,072) 515 (361-846) 832 (294-1,024) 342 (220-554) 0.0143
IP-10 (pg/mL) 1,349 (717-2,120) 1,053 (631-2,479) 882 (580-2,265) 1,596 (482-1,996) 1,153 (646-2,215) 0.7356
MIP-1b (pg/mL) 24 (16-51) 30 (21-49) 28 (18-61) 43 (32-55) 26 (15-33) 0.2005
G-CSF (pg/mL) 29 (12-69) 39 (17-89) 32 (14-64) 35 (19-434) 31 (11-179) 0.4916
GM-CSF (pg/mL) 6.1 (3.2-14.4) 11.9 (3.3-32.5) 6.7 (4.2-14.4) 9.4 (3.8-17.4) 5.4 (2.6-12.5) 0.1754
Anti-inflammatory cytokines
IL-10 (pg/mL) 6.2 (1.9-25.8) 17.8 (4.7-55) 8.3 (1.0-22.9) 24.5 (5.9-40.2) 5.1 (1.9-12.3) 0.0790
IL-1ra (pg/mL) 19 (8-47) 41 (13-100) 16 (8-49) 25 (14-37) 16 (9-33) 0.1666
Other cytokines
IFNc (pg/mL) 7 (2-27) 6 (3-16) 11 (3-24) 8 (4-17) 2 (1-28) 0.4394
IFNa2 (pg/mL) 23 (9-54) 41 (20-97) 19 (5-55) 30 (11-57) 17 (8-29) 0.0447
Eotaxin (pg/mL) 122 (91-176) 130 (88-180) 131 (89-214) 91 (67-178) 93 (79-116) 0.0782
IL-17a (pg/mL) 3.7 (1.3-22.7) 4.4 (1.9-13) 2.9 (1.6-14.4) 8.1 (5.4-28.7) 2.8 (1.5-11.8) 0.5340
IL-7 (pg/mL) 3.0 (1.6-8.2) 5.8 (2.1-11.1) 2.7 (1.2-7.5) 6.4 (2.2-18.5) 2.2 (0.7-11.9) 0.0966
EGF (pg/mL) 17 (9-48) 20 (9-32) 14 (6-33) 20 (9-26) 16 (3-62) 0.9015
VEGF (pg/mL) 97 (34-286) 109 (28-240) 84 (27-127) 91 (56-148) 62 (14-299) 0.7647
Albumin oxidation fractions†
HMA (%) 44 (32-55) 44 (32-55) 49 (39-57) 32 (19-49) 48 (35-63) 0.2151
HNA11HNA2 (%) 53.5 (42.6-65.7) 53.6 (41.8-66.7) 50.3 (42.8-59.6) 68.2 (50.6-80.9) 51.6 (37.4-64.7) 0.2489
HNA2 (%) 9.6 (5.1-14.8) 12.3 (8.0-15.3) 8.6 (7.0-13.3) 10.3 (6.5-14) 7.0 (3.9-10.7) 0.0682
Data are median (IQR).
*P value overall.
†According to the redox state at Cys34.
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STRENGTH OF THE
ASSOCIATION OF MARKERS OF
SI AND OF SCD WITH THE
FREQUENCY AND SEVERITY OF
ACLF OR ACLF-RF AT
ENROLLMENT AND THE COURSE
OF ACLF DURING
HOSPITALIZATION
IL-8, IL-6, and HNA2, the SI markers more closely
associated with the presence and severity of ACLF at
enrollment (Tables 1 and 2), and PRC were analyzed
for this purpose. PCC was not included in this analysis
because of its low ability for the assessment of SCD in
patients with ACLF-RF.
Figure 1 shows the distribution of patients with (red
dots) and without (green dots) ACLF according to
baseline values of PRC and IL-8 (left) or HNA2
(right) in the whole series. Patients with ACLF were
predominantly distributed in the right part of the
figures (higher degree of SI; upper panels), and the
strength of association of ACLF with both SI markers
was greater than that with PRC (lower panels). A sim-
ilar pattern of distribution was obtained with IL-6
(Supporting Fig. S2), with IL-8, IL-6 (not shown),
and HNA2 after excluding patients with active alco-
holism (Supporting Fig. S3) or with IL-8, IL-6 (not
shown), and HNA2 when only patients with ACLF-
RF were considered (Supporting Fig. S4).
Among the patients with ACLF, only 2 (1.7%)
showed normal values (below the 95th percentile of
the distribution in healthy subjects) of IL-6 and none
had normal values of IL-8. In contrast, 17.7% showed
normal PRC values (P < 0.001) and 8.0% presented
normal HNA2 values (P < 0.001; Fig. 2A). The corre-
sponding percentages in relation to patients with
ACLF-RF were 0%, 0.8%, 16.4%, and 8%, respective-
ly (P < 0.001; Fig. 2B). The corresponding values after
excluding patients with active alcoholism are repre-
sented in Supporting Fig. S5.
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FIG. 1. (A,B) Scatterplots of individual patients classified by the presence (red dots) or absence (green dots) of ACLF according to
individual values of PRC and IL-8 (left) or HNA2 (right). Two cut-off points for each marker divide each cohort into three tertiles
(T1, lower values; T2, intermediate values; T3, higher values). Patients with ACLF are predominantly in the right part of the panels
(higher degree of SI). (C,D) Presence of ACLF across the three tertiles of both PRC and IL-8 and PRC and HNA2. Differences in
the prevalence of ACLF within tertiles (T2 vs. T1 and T3 vs. T2) were more significant with IL-8 and HNA2 than with PRC.
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The logistic regression model showed that the
presence of ACLF was independently associated
with IL-6, IL-8, and HNA2, but not with PRC (log
PRC: relative risk [RR], 1.05; confidence interval
[CI], 0.94-1.16; P 5 0.413; log IL-8: RR, 1.73; CI,
1.40-2.14; P < 0.001; log IL-6: RR, 1.33; CI, 1.12-
1.57; P < 0.001; log HNA2: RR, 2.78; CI, 2.07-
3.71; P < 0.001). Only IL-8 and HNA2 were found
to be significantly associated with the presence
of ACLF-RF (RR, 1.45; 95% CI, 1.17-1.80; P <
0.00; and RR, 2.80; 95% CI, 1.98-3.95; P < 0.001,
respectively).
The step-wise linear regression model fitted for
CLIF-C Organ Failure Score based on the significance
of the increase in model R-square allowed to select
HNA2 (P < 0.0001) and both cytokines (IL-8, P <
0.0001; IL-6, P 5 0.0008) as the markers most
strongly related to severity of ACLF. Similarly, the
step-wise model fitted for serum creatinine allowed to
select HNA2 (P < 0.0001) and IL-6 (P 5 0.0114) as
the markers more strongly related to severity of renal
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FIG. 2. Scatterplots of individual values of PRC, IL-8, IL-6, and HNA2 in patients with ACLF (A) and with ACLF associated
with renal failure (B). Horizontal lines represent the upper normal limits (95% percentile of the distribution of values in healthy
subjects).
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failure. In both models, PRC did not contribute signif-
icantly to improve the final R-square.
There was a significant association between changes
in markers of SI during hospitalization and the course
of ACLF (Table 4). Improvement of ACLF was asso-
ciated with decrease, whereas worsening of ACLF was
associated with increase, in IL-6, IL-8, and HNA2.
Inflammatory markers did not change in the steady
form of ACLF or in patients with no ACLF through-
out the study. In contrast, no relationship was observed
between changes in PRC and the clinical course of
ACLF.
SI AND MORTALITY
The strength of association between SI, SCD, and
short-term mortality were also assessed considering
IL-8, IL-6, HNA2, and PRC values. Baseline values
of IL-8, IL-6 (not shown), and HNA2, but not of
PRC, were strongly associated with 28-day mortality
(Fig. 3) and 90-day mortality (Supporting Fig. S6).
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Similarly, there was a significant association between
the course of SI during hospitalization and the 28-
day and 90-day mortality (Table 5). One hundred
three patients had CRP data available at enrollment
and at the last follow-up assessment. Changes in
CRP from enrollment in those patients who sur-
vived at 28 (median, 24.0; IQR 213.121.6) and
90 days (median, 22.4; IQR, 211.121.9) were not
significantly different from those corresponding to
patients who died (median, 21.3; IQR, -19.6-3.7;
and median, 27.1; IQR, 220.720; P values,
0.4918 and 0.2044, respectively). Twenty-eight-day
and 90-day mortality rates were also significantly
associated (P < 0.0001) with SIRS at enrollment
(23 of 78 patients with SIRS [29.5%] and 47 of
433 without SIRS [10.6%] died within 28 days after
enrollment; mortality rates were 42.9% and 21.6%,
respectively, at 90 days).
Eighteen patients showed extremely high levels of
IL-8 (>800 UI/mL) and/or IL-6 (>1,000 UI/mL) at
enrolment (Fig. 2). The prevalence of severe forms of
ACLF (grades 2 or 3) and the 28-day mortality rate in
this group of patients (39% and 28%, respectively) was
higher (P 5 0.0833 and P 5 0.0774) than in the rest
of the patients (21% and 13%, respectively).
Discussion
The discussion of the article is divided in four parts:
(1) role of SI in the pathogenesis and clinical course of
AD and ACLF; (2) cytokine response; (3) mecha-
nisms of organ failure in ACLF; and (4) relationship
between SI and mortality.
The first part of the analysis (Tables 1–3) strongly sug-
gests that SI is a major mechanism of AD and ACLF
and supports most of the proposals of the SI hypothesis:
(1) AD of cirrhosis occurs in the setting of severe SI and
oxidative stress; and (2) SI is significantly more severe in
patients with ACLF than in those without ACLF. Inter-
estingly, the reported levels of IL-6, IL-8, and TNFa in
patients with severe sepsis, a condition also associated
with organ failure, are similar to those found in our
patients with ACLF(23-25); (3) severity of SI correlates
closely with severity of ACLF; and, finally, (4) the course
of SI during hospitalization is strongly associated with
the course of AD and ACLF (development of ACLF
during hospitalization in patients without ACLF at
enrollment or improvement, steady coursel or worsening
of ACLF in patients with ACLF at enrollment).
The characterization of cytokine response in our
patients (second part of the analysis; Tables 1–3 and
TABLE 4. Relationship Between ACLF Course, Plasma Concentrations of Renin (PRC), and Inflammation Markers
Parameter n Enrollment Last Assessment P Value*
PRC (microIU/mL)
Improvement† 71 113.5 (27.5-294.3) 82.9 (23.3-330.4) 0.9187
No change† 26 93.1 (57.6-362.5) 262.3 (87.0-1,212) 0.8450
Worsening† 40 168.6 (81.7-1,508.0) 259.7 (44.3-3,023.0) 0.7415
Non-ACLF patients‡ 96 111.5 (29.0-284.1) 110.0 (59.5-251.4) 0.9188
IL-6 (pg/mL)
Improvement 71 32.2 (13.1-104.4) 25.5 (12.2-46.7) 0.0002
No change 26 66.8 (25.2-125.5) 50.1 (19.8-117.7) 0.8589
Worsening 41 34.3 (17.7-111.2) 75.9 (20.6-134.3) 0.0744
Non-ACLF patients 87 25.0 (13.0-42.0) 16.5 (9.6-33.5) 0.0012
IL-8 (pg/mL)
Improvement 72 89.5 (36.7-174.3) 56.7 (35.6-119.1) 0.0003
No change 26 118.8 (65.4-209.6) 186.8 (72.7-268.0) 0.8450
Worsening 41 82.7 (48.9-136.7) 116.0 (52.9-198.6) 0.1196
Non-ACLF patients 98 40.8 (22.7-75.4) 38.7 (22.4-68.7) 0.6137
HNA2 (%)
Improvement 72 9.6 (5.3-14.1) 8.9 (5.0-13.4) 0.2215
No change 25 15.1 (11.0-20.3) 15.8 (11.2-20.5) 0.6383
Worsening 41 10.7 (8.1-13.3) 13.2 (9.6-18.4) 0.0020
Non-ACLF patients 98 6.3 (3.3-9.4) 6.1 (2.1-11.7) 0.3099
Data are median (IQR).
*Wilcoxon signed rank-sum test.
†“Improvement”/“worsening”: reduction/increase of 1 grade from enrollment in ACLF classification. “No change”: same classification
as at enrollment in ACLF patients.
‡Non-ACLF patients: patients without ACLF throughout the whole study.
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Supporting Table S7; Supporting Fig. S1) disclosed
interesting features. Whereas all the 17 cytokines and
chemokines included in the main analysis were signifi-
cantly increased in patients with AD with respect to
healthy controls, only those involved in innate immune
response were clearly up-regulated in patients with
ACLF with respect to those without ACLF. Indeed,
we found that patients with ACLF had a predomi-
nance of proinflammatory cytokines (i.e., TNFa and
IL-6) and chemokines (IL-8, MCP-1, IP-10, and
MIP-1b). These patients also had increased levels of
G-CSF and GM-CSF, key regulatory cytokines that
target committed progenitors to promote differentia-
tion and activation of monocytes and neutrophils.(26)
In contrast, among other cytokines that are involved in
the activation and shaping of the adaptive immune sys-
tem (IFNc, IL-17a, and IL-7), IFNc was only slightly
higher in patients with ACLF than in those without.
These findings suggest that whereas activation of both
the innate and adaptive immune systems participates
in the SI associated with AD, a dysregulated innate
immune response might be the predominant mecha-
nism in progression of AD to ACLF.
The assessment of the overall cytokine profile
showed that not only proinflammatory molecules, but
also major anti-inflammatory cytokines such as IL-10
and IL-1ra were increased in patients with AD with
and without ACLF, indicating a generalized activation
of the inflammatory cytokines. There was, however, a
clear unbalance in favor of proinflammatory cytokines,
as indicated by the significantly higher IL-6/IL-10
and IL-8/IL-10 ratios observed in patients with and
without ACLF as compared to healthy subjects.
Another outstanding feature was the observation of
clear differences in cytokine profile of patients with
ACLF according to the type of PE. Patients with
active alcoholism as PE exhibited very high IL-8 levels,
as described.(27,28) Such increase in IL-8 was observed
both in patients with and without AAH, although the
grade of increase was greater in the former group than
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FIG. 3. (A,B) Scatterplots of patients who died (red dots) or survived (green dots) at 28 days after enrollment according to individual
values of PRC and IL-8 (left) or human HNA2 (right). Two cut-off points for each marker divide each cohort into three tertiles (T1,
lower values; T2, intermediate values; T3, higher values). Patients who died are predominantly in the right part of the panels (higher
degree of SI). (C,D) Mortality rates observed within each tertile of both PRC and IL-8 and PRC and HNA2. Differences in mortali-
ty rates within tertiles (T2 vs. T1 and T3 vs. T2) were statistically significant only with IL-8 and HNA2.
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in the second. Patients with bacterial infection had a
characteristic increase of a set of inflammatory cyto-
kines. Finally, patients with other or without PE had
no differential increase in any cytokine with respect to
patients with active alcoholism or bacterial infection as
PE. These data suggest specific mechanisms for SI,
depending on the underlying trigger of ACLF. They
also suggest that ACLF in patients with unidentifiable
PE is unlikely related to unrecognized bacterial infec-
tion. Finally, they support a cause-to-effect relation-
ship between PE, SI, and ACLF development. This
suggestion, however, does not exclude other mecha-
nisms. In fact, dysfunctional or damaged organs by
itself may stimulate cytokine and reactive oxygen spe-
cies production(29) and therefore contribute to develop-
ment and/or progression of ACLF.
It is important to note that increased plasma levels
of G-CSF, GM-CSF, TNFa, IL-6, and IFNc have
been shown to participate in the process called
“emergency hematopoiesis,” which develops in the
context of SI.(30,31) Therefore, the activation of these
cytokines found in patients with ACLF probably con-
tributes to the leukocytosis associated with this syn-
drome and explains the close relationship between
WBC, ACLF severity, and patient prognosis.(1,3)
The mechanism by which SI induces ACLF was
explored in the third part of the analysis (Figs. 1 and 2
and Supporting Figs. S2, S3, S4, and S5, and logistic
regression and step-wise linear regression models).
Renal failure is a well-recognized complication in
patients with cirrhosis and bacterial infections,(32) and
evidences have been presented suggesting that it may
be related to a sequence of events initiated by an exag-
gerated systemic inflammatory response that induces
aggravation of splanchnic arterial vasodilation and
impairment in cardiac output, homeostatic activation of
endogenous neurohormonal systems to maintain arterial
pressure, renal vasoconstriction and vasoconstriction in
other organs (i.e., liver and brain), renal hypoperfusion,
and renal failure.(20,22) Our results showing that ACLF
develops in the setting of an accentuation in the SI and
SCD already present in patients with AD support that
this sequence of events is also important in the patho-
genesis of the syndrome.
However, several other findings obtained in the four
analyses assessing the strength of association of SI and
SCD with ACLF strongly suggest that the mechanism
of ACLF is far more complex. (1) Whereas SI at
enrollment (estimated by IL-6, IL-8, and HNA2) was
strongly related with frequency and severity of ACLF,
TABLE 5. Changes from Enrollment (Median and IQR) in Plasma Concentrations of Renin (PRC) and Inflammation
Markers According to Mortality at 28 and 90 Days After Enrollment
28-Day Survivors 28-Day Deaths
Marker N Enrollment Last Assessment Change N Enrollment Last Assessment Change
PRC
(microIU/mL)
138 116.7 (30.1-332.5) 119.8 (27.8-407) -6.8 (-113.6-62.2) 37 99.0 (32.5-353.1) 201.9 (57.7-1,156) 25.3 (-51.8-317.2)
IL-6
(pg/mL)
137 32.2 (15.0-106.3) 26.3 (13.5-58.8)* -5.3 (-36.9-10.5) 38 51.5 (21.2-173.1) 63.3 (31.4-168.9) 19.3 (-43.4-68.6)§
IL-8
(pg/mL)
139 71.7 (35.6-153.7) 65.9 (36.0-125.0)* -3.8 (-41.7-16.3) 38 107.8 (74.8-246.4) 147.3 (79.2-260.7) 6.7 (-42.1-62.2)
HNA2
(%)
139 9.5 (5.6-14.9) 10.7 (6.5-15.3) -0.1 (-3.4-3.3) 36 12.9 (8.5-16.5) 14.1 (9.5-18.8)* 2.4 (-1.4-6.4)‡
90-Day Survivors 90-Day Deaths
Marker N Enrollment Last Assessment Change N Enrollment Last Assessment Change
PRC
(microIU/mL)
105 108.7 (26.4-282.0) 89.6 (23.2-378.2) -0.2 (-87.9-56.5) 66 171.3 (40.9-1,576) 246.8 (64.1-1,212) 19.7 (-171.2-204.8)
IL-6
(pg/mL)
104 40.3 (15.3-120.1) 23.6 (11.7-49.8)† -8.4 (-57.4-3.0) 67 31.9 (17.3-117.8) 48.9 (25.5-129.2)* 14.7 (-12.2-60.9)§
IL-8
(pg/mL)
106 83.2 (35.6-157.6) 56.4 (35.3-105.4)* -7.2 (-50.7-9.2) 67 84.7 (50.5-204.6) 124.2 (64.8-227.1) 9.6 (-717.1-77.0)§
HNA2
(%)
106 9.4 (5.6-13.6) 9.3 (5.3-15.0) 0.03 (-3.3-3.1) 65 12.5 (7.4-16.4) 13.4 (9.4-17.4)* 1.4 (-2.5-6.4)
Data are median (IQR).
*P < 0.05 versus enrollment.
†P < 0.01 versus enrollment.
‡P < 0.05 versus change from baseline in survivors.
§P < 0.001 versus change from baseline in survivors.
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this was not true for SCD (estimated by PRC); (2) the
clinical course of ACLF was associated with parallel
changes in plasma levels of SI markers, but not with
PRC; (3) PRC was normal or slightly increased in
many patients with ACLF or with ACLF-RF. In con-
trast, IL-6 and IL-8 were markedly increased in almost
all these patients. (4) The logistic regression model
assessing those markers (IL-8, IL-6, HNA2, and/or
PRC) independently associated with presence of
ACLF or ACLF-RF and the linear regression model
assessing the correlation of IL-8, IL-6, HNA2, and
PRC with severity of ACLF and of ACLF-RF
showed significant relationships with IL-6, IL-8, and
HNA2, but not with PRC. These results strongly sug-
gest that nonhemodynamic mechanisms mostly medi-
ate the deleterious effects of SI in organ function and
participate in the pathogenesis of ACLF.
Three lines of evidence support this contention.(33-38)
The first includes investigations showing that the
extension of SI into the organs (i.e., as a consequence
of extremely high circulating plasma levels of inflam-
matory mediators and perhaps also of proinflammatory
molecules [PAMPS and DAMPS]) may lead to organ
failure through direct deleterious effects on microcircu-
latory homeostasis, mitochondrial function, and cell
survival. The second includes investigations in patients
and experimental animals with severe sepsis, a condi-
tion with many similarities with ACLF, showing that
renal failure may occur in the setting of hyperdynamic
circulation and normal renal perfusion. Finally, the
third derives from a recent study on transjugular kidney
biopsies in 65 patients with cirrhosis awaiting LT.
Among the numerous glomerular, vascular, and acute
or chronic tubulointerstitial lesions found in these
patients, only cortical and medullary infiltration by
mononuclear cells and polymorphonuclear leukocytes
associated with tubular cell injury was independently
associated with the presence of renal failure.(39) There-
fore, as in severe sepsis, single- or multi-organ failure
in cirrhosis is probably the result of a complex process
involving numerous mechanisms, including impair-
ment in systemic circulatory and local microcirculatory
functions, microcirculatory thrombosis, mitochondrial
and cell dysfunction, and cell death.
A final important observation was that IL-8, IL-6,
and HNA2 at enrollment and their follow-up changes
during hospitalization were directly associated with 28-
day and 90-day mortality (fourth part of the analysis;
Fig. 3 and Supporting Fig. S6; Table 5). Patients who
died showed significantly higher baseline plasma levels
of these mediators than those who survived. Moreover,
plasma concentrations of IL-6, IL-8, and HNA further
increased during hospitalization in the former and
decreased in the latter group of patients. Sequential
measurements of inflammatory mediators could there-
fore be a sensitive tool to assess treatment effectiveness
and predict prognosis in patients with ACLF.
In summary, the current study supports the SI hypoth-
esis of AD and ACLF in cirrhosis. (1) AD occurs in the
setting of very high plasma levels of cytokines and oxi-
dized albumin; (2) ACLF develops when there is a fur-
ther increase in these inflammatory mediators; and (3)
although ACLF frequently occurs in the setting of severe
SCD, inflammatory mediators are more strongly associ-
ated with the frequency, severity, and clinical course of
ACLF than PRC, indicating that both hemodynamic
and nonhemodynamic mechanisms are important in the
pathogenesis of ACLF. Different profiles of cytokine
response were observed. Whereas SI in AD was associat-
ed with very high levels of cytokines involved in both the
innate and adaptive immune systems, cytokines associat-
ed with ACLF were mainly cytokines involved in the
innate immune response. Different profiles of cytokine
response were also identified according to PEs of ACLF.
Severity of SI at enrollment and progression or regression
of SI during hospitalization were closely associated with
short-term prognosis. Sequential measurement of inflam-
matory mediators may therefore be useful as predictors of
treatment effectiveness and patient prognosis.
Appendix
Alphabetical list of CANONIC Study Investigators:
Patricia Aguilar Melero, Hospital Universitario Reina
Sofıa, Centro de Investigacion Biomedica en Red
Enfermedades Hepaticas y Digestivas (CIBERehd),
Instituto Maimonides de Investigacion Biomedica de
Cordoba (IMIBIC), Cordoba, Spain.
Rafael Ba~nares, Hospital General Universitario
Gregorio Mara~non, Instituto de Investigacion Sani-
taria Gregorio Mara~non (IiSGM), Centro de Inves-
tigacion Biomedica en Red Enfermedades Hepaticas
y Digestivas (CIBERehd), School of Medicine, Uni-
versidad Complutense, Madrid, Spain.
Massimo Bocci, Department of Gastroenterology
and Hepato-Pancreatology, Erasme Hospital, Uni-
versite Libre de Bruxelles, Brussels, Belgium.
Paolo Caraceni, Semeiotica Medica, Policlinico S.
Orsola-Malpighi, Department of Medical and Sur-
gical Sciences, University of Bologna, Bologna,
Italy.
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Marıa-Vega Catalina, Hospital General Universi-
tario Gregorio Mara~non, Instituto de Investigacion
Sanitaria Gregorio Mara~non (IiSGM), Centro de
Investigacion Biomedica en Red Enfermedades
Hepaticas y Digestivas (CIBERehd), Madrid, Spain.
Jun Liong Chin, Liver Unit, St Vincent’s Universi-
ty Hospital, Dublin, Ireland.
Mar Concepcion, Department of Gastroenterology,
Hospital de la Santa Creu i Sant Pau, Barcelona, Uni-
versitat Autonoma de Barcelona, Barcelona, Spain.
Audrey Coilly, Centre Hepato-Biliaire, Hôpital
Paul-Brousse, Assistance Publique-Hôpitaux de Paris,
Villejuif, France.
Carme Deulofeu, Data Management Centre, CLIF
Consortium, Hospital Clinic, Barcelona, Spain.
Laure Elkrief, Service d’Hepatologie, Hôpital
Beaujon, Assistance Publique Hôpitaux de Paris,
Clichy, France; Inserm U773, Centre de Recherche
Biomedicale Bichat-Beaujon CRB3, Clichy and
Paris, France; and Universite Paris Diderot-Paris 7,
Paris, France.
Javier Fernandez, Liver Unit, Hospital Clinic, Uni-
versity of Barcelona, CLIF Consortium Centro de
Investigacion Biomedica en Red Enfermedades Hepa-
ticas y Digestivas (CIBERehd), Barcelona, Spain.
Elisabetta Gola, Unit of Internal Medicine and
Hepatology, Department of Medicine, DIMED,
University of Padova, Padova, Italy.
Andrea de Gottardi, University Clinic of Visceral
Surgery and Medicine of Berne, Berne, Switzerland.
Henning Grøenbæk, Department of Medicine V,
Unit of Hepatology and Gastroenterology, Aarhus
University Hospital, Aarhus, Denmark.
AnneKristin Hausen, Department of Internal Med-
icine I, University Hospital of Bonn, Bonn, Germany.
Ansgar W. Lohse, Department of Gastroenterolo-
gy and Hepatology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany.
Caterina Maggioli, Semeiotica Medica, Policlinico S.
Orsola-Malpighi, Department of Medical and Surgical
Sciences, University of Bologna, Bologna, Italy.
Daniel Markwardt, Liver Center Munich, Depart-
ment of Medicine 2, Klinikum der LMU M€unchen-
Grosshadern, Munich, Germany.
Javier Martinez, Servicio de Gastroenterologıa,
Hospital Universitario Ramon y Cajal, Madrid,
Spain.
Manuel de la Mata, Garcıa Hospital Universi-
tario Reina Sofıa, Centro de Investigacion Bio-
medica en Red Enfermedades Hepaticas y
Digestivas (CIBERehd), Instituto Maimonides de
Investigacion Biomedica de Cordoba (IMIBIC),
Cordoba, Spain.
P. Aiden McCormick, Liver Unit, St Vincent’s
University Hospital, Dublin, Ireland.
Francisco Mesonero, Servicio de Gastro-
enterologıa, Hospital Universitario Ramon y Cajal,
Madrid, Spain.
Jose Luis Montero Alvarez, Hospital Universitario
Reina Sofıa, Centro de Investigacion Biomedica en
Red Enfermedades Hepaticas y Digestivas (CIBER-
ehd), Instituto Maimonides de Investigacion Bio-
medica de Cordoba (IMIBIC), Cordoba, Spain
Rajeshwar P Mookerjee, Institute of Liver and
Digestive Health, Liver Failure Group, Royal Free
Campus, London, United Kingdom.
Christophe Moreno, Department of Gastroenterol-
ogy and Hepato-Pancreatology, Erasme Hospital,
Universite Libre de Bruxelles, Brussels, Belgium.
Bernhard Morrell, University Clinic of Visceral
Surgery and Medicine of Berne, Berne, Switzerland.
Christian Mortensen, Department of Gastroenter-
ology, Hvidovre Hospital, University of Copenhagen,
Copenhagen, Denmark.
Markus Peck-Radosavljevic, Department of Gas-
troenterology and Hepatology, Medical University of
Vienna, Vienna, Austria.
Alessandro Risso, Division of Gastroenterology
and Hepatology, San Giovanni Battista Hospital,
University of Turin, Turin, Italy.
Didier Samuel, Centre Hepato-Biliaire, Hôpital Paul
Brousse, Assistance Publique-Hôpitaux de Paris, Ville-
juif, France.
Macarena Simon-Talero, Servicio de Hepatologia,
Hospital Vall d’Hebron, Universitat Autonoma de
Barcelona, Centro de Investigacion Biomedica en
Red Enfermedades Hepaticas y Digestivas (CIBER-
ehd), Barcelona, Spain.
Elsa Sola, Liver Unit, Hospital Clinic de Barcelo-
na, IDIBAPS, CibereHD, Barcelona, Spain.
Pablo Solis-Mu~noz, Institute of Liver Studies and
the Cellular Biology of Inflammation, King’s College
London, London, United Kingdom.
German Soriano, Department of Gastroenterology,
Hospital de la Santa Creu i Sant Pau, Barcelona, Uni-
versitat Autonoma de Barcelona, Centro de Inves-
tigacion Biomedica en Red Enfermedades Hepaticas y
Digestivas (CIBERehd), Instituto de Salud Carlos III,
Barcelona, Spain.
Jan Sperl, Department of Hepatogastroenterology,
Institute for Clinical and Experimental Medicine,
Prague, Czech Republic.
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Walter Spindelboeck, Division of Gastroenterology
and Hepatology, Department of Internal Medicine,
Medical University of Graz, Graz, Austria.
Dominique Valla, Service d’Hepatologie, Hôpital
Beaujon, Assistance Publique Hôpitaux de Paris, Cli-
chy, France; Inserm U773, Centre de Recherche Bio-
medicale Bichat-Beaujon CRB3, Clichy and Paris,
France; and Universite Paris Diderot-Paris 7, Paris,
France.
Victor Vargas, Servicio de Hepatologia, Hospital
Vall d’Hebron, Universitat Autonoma de Barcelona,
Centro de Investigacion Biomedica en Red Enferme-
dades Hepaticas y Digestivas (CIBERehd), Barcelona,
Spain.
Hans Van Vlierberghe, Department of Gastroen-
terology and Hepatology, Ghent University Hospital,
Ghent, Belgium.
Wolfgang Vogel, Department of Gastroenterology
and Hepatology, Innsbruck Medical University, Inns-
bruck, Austria.
Henninge Wege, Department of Gastroenterology
and Hepatology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany.
Chris Willars, Liver Intensive Care Unit, King’s
College Hospital, London, United Kingdom.
Giacomo Zaccherini, Semeiotica Medica, Policli-
nico S. Orsola-Malpighi, Department of Medical
and Surgical Sciences, University of Bologna, Bolo-
gna, Italy.
Stefan Zeuzem, Department of Medicine I, JW
Goethe University Hospital, Frankfurt, Germany.
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